Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Worsening after rituximab treatment in anti-mag neuropathy.

× No keyword cloud information.

19 in total

1. Practical considerations on the use of rituximab in autoimmune neurological disorders.

Authors: Mixalis L Kosmidis; Marinos C Dalakas
Journal: Ther Adv Neurol Disord Date: 2010-03 Impact factor: 6.570

Review 2. Update on therapy of chronic immune-mediated neuropathies.

Authors: Chiara Briani; Dario Cocito; Marta Campagnolo; Pietro Emiliano Doneddu; Eduardo Nobile-Orazio
Journal: Neurol Sci Date: 2021-01-16 Impact factor: 3.307

3. Guillain-Barré syndrome after rituximab in a patient with idiopathic thombocytopenic purpura: a causal association?

Authors: Raquel Jaso; María Sierra; Jesús Calleja; Carmen Valero; Julio Pascual
Journal: J Neurol Date: 2009-11-22 Impact factor: 4.849

Review 4. Molecularly targeted therapies for dysimmune neuropathies.

Authors: Andreas A Argyriou
Journal: Mol Med Date: 2009-05-05 Impact factor: 6.354

5. Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges.

Authors: Klaus Lehmann-Horn; Helena C Kronsbein; Martin S Weber
Journal: Ther Adv Neurol Disord Date: 2013-05 Impact factor: 6.570

6. Plasma exchanges for severe acute neurological deterioration in patients with IgM anti-myelin-associated glycoprotein (anti-MAG) neuropathy.

Authors: M Baron; P Lozeron; S Harel; D Bengoufa; M Vignon; B Asli; M Malphettes; N Parquet; A Brignier; J P Fermand; N Kubis; Bertrand Arnulf
Journal: J Neurol Date: 2017-05-08 Impact factor: 4.849

Worsening after rituximab treatment in anti-mag neuropathy.

1. Practical considerations on the use of rituximab in autoimmune neurological disorders.

Review 2. Update on therapy of chronic immune-mediated neuropathies.

3. Guillain-Barré syndrome after rituximab in a patient with idiopathic thombocytopenic purpura: a causal association?

Review 4. Molecularly targeted therapies for dysimmune neuropathies.

5. Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges.

6. Plasma exchanges for severe acute neurological deterioration in patients with IgM anti-myelin-associated glycoprotein (anti-MAG) neuropathy.

Review 7. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies.

8. Pathogenesis and Treatment of Anti-MAG Neuropathy.

Review 9. [Rituximab in treatment for neuroimmunological diseases].

10. Rituximab in cryoglobulinemic peripheral neuropathy.